# Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters

> **NCT05972018** · PHASE4 · RECRUITING · sponsor: **Hartford Hospital** · enrollment: 14 (estimated)

## Conditions studied

- Aortic Aneurysm, Abdominal
- Abdominal Aortic Occlusion
- Aortoiliac Occlusive Disease
- Aortic Diseases

## Interventions

- **DRUG:** Liposomal bupivacaine
- **DRUG:** Ropivacaine
- **DRUG:** Bupivacain

## Key facts

- **NCT ID:** NCT05972018
- **Lead sponsor:** Hartford Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972018, "Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05972018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*